Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of tegobuvir and GS-9451 with peginterferon alfa-2a and ribavirin in chronic hepatitis C
2010-023952-10Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Feb 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegobuvir, vedroprevir, interferon alfa and ribavirin in hepatitis C virus infection (3 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained virologic response and Safety and tolerability. Started Feb 2011; status: terminated.
02
Drugs
tegobuvirvedroprevirinterferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-023952-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023952-10.